, Victoria, Australia, 3084 Biomed Research Unit-VIC-3084-113
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tran, Lloyd
OPV-NA831, NCT04540185: A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Enrolling by invitation
3
3600
US, RoW
Biological: oral polio vaccine, Oral Polio Vaccine (OPV), Comparable Placebo, Placebo comparator, NA-831, NA-81 is a neuroprotective drug, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, OPV and Drug combination, Comparable Placebo of Oral Polio Vaccine and Placebo of drug, Placebo Comparator
NeuroActiva, Inc., Biomed Industries, Inc.
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
11/22
12/22
NATADEX, NCT04452565: NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Recruiting
2/3
525
US
Drug: NA-831, NA-831 and Atazanavir, and Atazanavir, NA-831and Dexamethasone, Dexamethasone, Atazanavir and Dexamethasone
NeuroActiva, Inc., Biomed Industries, Inc.
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
12/23
12/23
NCT06564753: Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

Recruiting
2
125
RoW
Drug: Placebo daily and orally, NA-931 placebo, NA-931, dose 1, daily and orally, NA-931, NA-931, dose2, daily and orally, NA-931 dose 3, daily and orally, NA=931, NA-931 dose 4, daily and orally
NeuroActiva, Inc., Biomed Industries, Inc.
Weight Loss, Obesity, Body Weight, Body Weight Changes
01/25
02/25
NA-931-200, NCT06732245: Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Not yet recruiting
2
224
US, RoW
NA-931, Tirzepatide placebo, Tirzepatide, NA-931 Placebo, NA-931 150 mg + no Tirzepatide
Biomed Industries, Inc., Bioneurals Ltd
Obesity and Overweight
08/26
12/26
NEUROSIVIR, NCT04480333: Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

Recruiting
1
45
US
Drug: NA-831 - 0.10 mg/kg, NA-831 is a neuroprotective and neurogenesis drug, Placebo- 0.10 mg/kg, Placebo Comparator, Drug: NA-831 - 0.20 mg/kg, NA-81 is a neuroprotective drug, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, GS-5734 (Remdesivir) is an antiviral drug, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, GS-5734 (Remdesivir) is an anti-viral drug, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Combination therapy of NA-831 a neuroprotective drug and GS-5734 an antiviral drug, Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Combination therapy of NA-831, a neuroprotective drug and GS-5734, an antiviral drug, Placebo 0.20 mg + 2.00 mg/kg
NeuroActiva, Inc.
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
12/20
03/21
T2DM, NCT06615700: Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

Completed
1
74
RoW
NA-931, NA-931 is a quadruple receptor agonist, Placebo, Placebo of NA-931
Biomed Industries, Inc.
Overweight or Obesity, Type 2 Diabetes
08/24
09/24

Download Options